Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | BTK | Q06187 | 10/20 | 0.39 |
| ▸ | EGFR | P00533 | 8/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 3/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK7 | P50613 | 2/20 | 0.35 |
| ▸ | CCNH | P51946 | 2/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230902 | 0.92 | FFAR4 (0.38) | JAK3BTKEGFRCCNKCDK12 | |
| SCHEMBL30091793 | 0.82 | USP30 (0.48) | BTKCCNA2CDK2 | |
| SCHEMBL22431488 | 0.82 | USP30 (0.48) | BTKCCNA2CDK2 | |
| SCHEMBL21682732 | 0.78 | JAK2 (0.49) | JAK3 | |
| SCHEMBL28508298 | 0.77 | ALDH1A1 (0.46) | JAK3CCNKCDK12 | |
| SCHEMBL2318073 | 0.77 | BTK (0.40) | JAK3BTKEGFRCCNKCDK12 | |
| SCHEMBL22404993 | 0.77 | ALDH1A1 (0.52) | CCNA2CDK2 | |
| SCHEMBL30055472 | 0.77 | HSD11B1 (0.40) | CCNKCDK12 | |
| SCHEMBL15205915 | 0.76 | L3MBTL4 (0.41) | BTKEGFRCCNKCDK12 | |
| SCHEMBL15205859 | 0.76 | L3MBTL4 (0.41) | BTKEGFRCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | JAK3 23/4885BTK 1/4885EGFR 403/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | JAK3 25/4885BTK 1/4885EGFR 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.